Hiv November New

THE SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE 14 14. Starr SE, Fletcher CV, Spector SA, et al.; PACTG 382 Study Team. Pediatric AIDS Clinical Trials Group. Efavirenz liquid formulation in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002; 21: 659-663. 15. Saez-Llorens X, Violari A, Deetz CO, et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virusinfected children. Pediatr Infect Dis J 2003; 22: 216-224. 16. Chadwick EG, Rodman J, Palumbo P, et al. PACTG 1030 Study Team. A Prospective evaluation of pharmacologic, virologic, and immunologic parameters for lopinavir/ritonavir for HIV-1 infected infants < 6 months of age (abstract). In: 12th Conference on Retroviruses and Opportunistic Infections, February 2005, Boston, MA. 17. Pau AK, Capparelli EV, Holland D, Fomundam H, Matchaba GU, Moodley NK. Instability of lopinavir/ritonavir capsules at ambient temperature in subSaharan Africa: relevance to WHO antiretrovirals. AIDS 2005; 19: 1233-1234. 18. Krogstad P, Wiznia A, Luzuriaga K, et al. Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. Clin Infect Dis 1999; 28: 1109-1118. 19. Schuster T, Linde R, Wintergerst U, et al. Nelfinavir pharmacokinetics in HIVinfected children: a comparison of twice daily and three times daily dosing. AIDS 2000; 14: 1466-1468. 20. Hoody DW, Fletcher CV. Pharmacology considerations for antiretroviral therapy in human immunodeficiency virus (HIV)-infected children. Semin Pediatr Infect Dis 2003; 14: 286-294. 21. Capparelli EV, Mirochnick M, Danker WM, et al. PACTG Study 331 Team. Pharmacokinetics and tolerance of zidovudine in preterm infants. J Pediatr 2003; 142: 47-52. 22. Mirochnick M, Fenton T, Gagnier P, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis 1998; 178: 368-374. 23. Capparelli E, Blanchard S, Aweeka F, Acosta E. Population pharmacokinetics of nevirapine in infants and children – the impact of body size, age, and concomitant therapies (abstract). In: 6th International Workshop on Clinical Pharmacology of HIV Therapy 2005, Quebec City, CA. 24. Litalien C, Fay A, Compagnucci A, et al. Paediatric European Network for Treatment of AIDS Excecutive Committee. Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 2003; 22: 48-55. 25. Hazra R, Balis FM, Tullio AN, et al. Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virusinfected children. Antimicrob Agents Chemother 2004; 48: 124-129.